Tyloxapol

From Wikipedia, the free encyclopedia
Tyloxapol
Systematic (IUPAC) name
formaldehyde;oxirane;4-(2,4,4-trimethylpentan-2-yl)phenol
Clinical data
AHFS/Drugs.com International Drug Names
Legal status ?
Identifiers
CAS number 25301-02-4 YesY
ATC code R05CA01
PubChem CID 71388
DrugBank DB06439
ChemSpider 11052515 N
UNII Y27PUL9H56 N
KEGG D03261 N
ChEMBL CHEMBL1201548 N
Chemical data
Formula (C15H21O(C2H4O)m)n
Mol. mass variable
 N (what is this?)  (verify)

Tyloxapol is a nonionic liquid polymer of the alkyl aryl polyether alcohol type. It is used as a surfactant to aid liquefaction and removal of mucopurulent[citation needed] (containing mucus and pus) bronchopulmonary secretions,[1][2] administered by inhalation through a nebulizer[3] or with a stream of oxygen.

With intraperitoneal injection, tyloxapol also blocks plasma lipolytic activity, and thus the breakdown of triglyceride-rich lipoproteins. This mechanism is used to induce experimental hyperlipidemia in animals.[4]

References

  1. Sehgal, S. S.; Ewing, C. K.; Richards, T.; Taeusch, H. W. (1994). "Modified bovine surfactant (Survanta) versus a protein-free surfactant (Exosurf) in the treatment of respiratory distress syndrome in preterm infants: A pilot study". Journal of the National Medical Association 86 (1): 46–52. PMC 2607653. PMID 8151722. 
  2. Rubin, B. K.; Ramirez, O.; King, M. (1992). "Mucus rheology and transport in neonatal respiratory distress syndrome and the effect of surfactant therapy". Chest 101 (4): 1080–1085. doi:10.1378/chest.101.4.1080. PMID 1555424. 
  3. Drugs.com: Tyloxapol definition
  4. Kourounakis, A. P.; Victoratos, P.; Peroulis, N.; Stefanou, N.; Yiangou, M.; Hadjipetrou, L.; Kourounakis, P. N. (2002). "Experimental hyperlipidemia and the effect of NSAIDs". Experimental and molecular pathology 73 (2): 135–138. doi:10.1006/exmp.2002.2449. PMID 12231215. 


This article is issued from Wikipedia. The text is available under the Creative Commons Attribution/Share Alike; additional terms may apply for the media files.